Disitamab vedotin

Generic Name: Disitamab vedotin

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2136633-23-1

Unique Ingredient Identifier: RB3U3A1S27

Background: Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.

Indication: 用于至少接受过2个系统化疗的HER2过表达局部晚期或转移性胃癌（包括胃食管结合部腺癌）的患者，HER2过表达定义为HER2免疫组织化学检查结果为2+或3+。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Neoplasms

Interventions: Drug: Disitamab vedotin
Drug: Tislelizumab

First Posted Date: 2022-08-09

Last Posted Date: 2022-10-21

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 29

Registration Number: NCT05493683

Locations: 🇨🇳
Changzhou NO.2 People's Hospital, Changzhou, Jiangsu, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China

and more 3 locations

Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

Phase 2

Not yet recruiting

Conditions: Colorectal Neoplasms

Interventions: Drug: Pembrolizumab
Drug: Disitamab vedotin

First Posted Date: 2022-04-19

Last Posted Date: 2022-04-20

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 30

Registration Number: NCT05333809

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Phase 2

Recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: disitamab vedotin
Drug: pembrolizumab

First Posted Date: 2021-05-10

Last Posted Date: 2024-10-24

Lead Sponsor: Seagen Inc.

Target Recruit Count: 332

Registration Number: NCT04879329

Locations: 🇦🇺
GenesisCare North Shore (Oncology), St Leonards, Other, Australia
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
City of Hope, Duarte, California, United States

and more 79 locations

A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: RC48

First Posted Date: 2020-03-17

Last Posted Date: 2023-12-18

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 37

Registration Number: NCT04311034

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy